19th November 2016
Pancreatic cancer is the fourth most deadly form of the disease in France and is so difficult to treat that it is set to become the second most deadly by 2020, experts have warned.
But researchers at INSERM and the Toulouse Cancer Research Centre believe a chance discovery could be key to combating disease after they discovered the absence of a key enzyme slowed the progression and development of pancreatic tumours.
The molecule, cytidine deaminase, appears to play an important role in the growth of the tumours, researchers said. The idea is to target it and slow down the progression of the disease.
Their research is one of five to have been selected for further research by the Toulouse Cancer Santé Foundation, which wants to raise €1m to fund the projects. The public can support the foundation's work by making a donation via its website at http://www.toulousecancer.fr/en/